HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Further trials of nifurtimox in mucocutaneous leishmaniasis.

Abstract
At a dosage level of 8 to 10 mg/kg body-weight daily for 120 days nifurtimox was associated with clinical healing of cutaneous leishmaniasis in five of eight patients. At a dosage level of 20 mg/kg body-weight daily for 10 days in six of 10 patients the skin ulcer healed. Results and the reasons why both schemes are impracticable are briefly discussed.
AuthorsM F Guerra, P D Marsden, C C Cuba, A C Barretto
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene (Trans R Soc Trop Med Hyg) Vol. 75 Issue 3 Pg. 335-7 ( 1981) ISSN: 0035-9203 [Print] England
PMID7324099 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Nitrofurans
  • Nifurtimox
Topics
  • Adolescent
  • Adult
  • Aged
  • Child
  • Drug Administration Schedule
  • Female
  • Humans
  • Leishmaniasis (drug therapy)
  • Leishmaniasis, Mucocutaneous (drug therapy)
  • Male
  • Middle Aged
  • Nifurtimox (administration & dosage, adverse effects, therapeutic use)
  • Nitrofurans (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: